

KELLOGG, HANSEN, TODD, FIGEL & FREDERICK, P.L.L.C.

SUMNER SQUARE  
1615 M STREET, N.W.  
SUITE 400  
WASHINGTON, D.C. 20036-3215

(202) 326-7900

FACSIMILE

(202) 326-

March 27,

Application granted. The redacted document (Doc. 42) shall remain the publicly-filed version, and the unredacted version (Doc. 41) shall remain under seal.

SO ORDERED.

  
Philip M. Halpern  
United States District Judge

Dated: White Plains, New York  
March 31, 2025

*Via ECF*

The Honorable Philip M. Halpern  
The Hon. Charles L. Briant Jr.  
Federal Building and United States Courthouse  
300 Quarropas Street, Room 530  
White Plains, New York 10601

HalpernNYSDChambers@nysd.uscourts.gov

Re: ***Regeneron Pharmaceuticals, Inc. v. Sanofi Biotechnology SAS, Sanofi S.A.,  
sanofi-aventis U.S. LLC, and Genzyme Corporation***  
**Case No. 7:24-cv-08751-PMH (S.D.N.Y.)**

Dear Judge Halpern:

We represent Regeneron in this action and submit this Letter Motion to Seal in accordance with Federal Rule of Civil Procedure 5.2, Local ECF Rules and Instructions 6.5, and this Court's Individual Practice Rule 5.B.

Regeneron respectfully requests that the Court seal the unredacted version of its Response to Sanofi's Pre-Motion Letter that Regeneron will file contemporaneously with this Letter Motion. Regeneron will also contemporaneously file a redacted public version of its Response to Sanofi's Pre-Motion Letter. The redacted version includes only one, narrowly tailored redaction to protect the same confidential information discussed in Sanofi's motion to seal, *see* ECF No. 37, which the Court granted, *see* ECF No. 39.

This motion to seal is unopposed.

Respectfully submitted,

/s/ Andrew E. Goldsmith

Andrew E. Goldsmith (*admitted pro hac vice*)  
Counsel for Regeneron Pharmaceuticals, Inc.

cc: All parties of record (via ECF)